Study guide

15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value

Combined Medical Services Examination UPSC CMS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Logistics & Pattern

1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths

2 Chapter 2: General Medicine - Cardiology & Respiratory

2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism

3 Chapter 3: General Medicine - Gastroenterology & Hepatology

3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes

4 Chapter 4: General Medicine - Nephrology & Endocrinology

4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction

5 Chapter 5: General Medicine - Neurology, Haematology & Infection

5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue

6 Chapter 6: General Medicine - Emergency Medicine & Toxicology

6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology

7 Chapter 7: Paediatrics - Neonatology & Child Growth

7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones

8 Chapter 8: Paediatrics - Child Health & Nutrition

8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning

9 Chapter 9: Surgery - General Surgery, Wounds & Shock

9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery

10 Chapter 10: Surgery - Surgical Specialties I

10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi

11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia

11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease

12 Chapter 12: Obstetrics - Antenatal Care & Complications

12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management

13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH

13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care

14 Chapter 14: Gynaecology & Family Planning

14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods

15 Chapter 15: PSM - Epidemiology & Biostatistics

15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing

16 Chapter 16: PSM - Disease Epidemiology & Programmes

16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling

17 Chapter 17: PSM - Health Planning & Environmental Health

17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education

15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value

Key Takeaways Explain This Topic AI

Screening tests identify unrecognized subclinical disease in apparently healthy individuals; diagnostic tests confirm disease in symptomatic or screen-positive individuals.

Sensitivity = a / (a + c) evaluates the test's ability to correctly identify diseased persons (SNOUT: Sensitive test when Negative rules OUT disease).

Specificity = d / (b + d) evaluates the test's ability to correctly identify non-diseased persons (SPIN: Specific test when Positive rules IN disease).

Positive Predictive Value (PPV = a / [a + b]) depends heavily on disease prevalence: as prevalence increases, PPV increases sharply while Sensitivity and Specificity remain constant.

Parallel testing increases overall Sensitivity and NPV (useful when missing a case is dangerous); Serial testing increases overall Specificity and PPV (useful for costly/invasive confirmatory steps).

Last updated: July 2026

  • Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value
  • 1. Screening Concept vs. Diagnostic Test

Screening is defined as the search for unrecognized disease or defect by applying rapid tests, examinations, or other procedures in apparently healthy target populations.

Wilson and Jungner Criteria for Screening (WHO)

The condition should be an important health problem .

There should be an accepted treatment for patients with recognized disease.

Facilities for diagnosis and treatment should be available.

There should be a recognizable latent or early symptomatic stage .

There should be a suitable test or examination .

The test should be acceptable to the population.

The natural history of the condition should be adequately understood.

There should be an agreed policy on whom to treat as patients.

The cost of case-finding should be economically balanced in relation to overall medical care expenditure.

Case-finding should be a continuing process and not a 'once and for all' project.

Key Differences Between Screening and Diagnostic Tests

  • Attribute Screening Test Diagnostic Test
  • Target Population Apparently healthy, asymptomatic individuals Symptomatic patients or screen-positive cases
  • Test Objective Presumptive identification of early disease Definitive establishment of diagnosis
  • Cost & Simplicity Simple, rapid, inexpensive, non-invasive Elaborate, complex, expensive, often invasive

Cut-off Point Set to optimize Sensitivity (avoid missing cases) Set to optimize Specificity (avoid false alarms)

  • Basis for Action Requires confirmatory diagnostic testing Forms basis for definitive therapy
  • 2. The 2x2 Evaluation Matrix

To evaluate any screening test against a gold standard diagnostic benchmark, a 2x2 contingency matrix is constructed:

Screening Test Result Disease Present ( D + D+ D + ) Disease Absent ( D − D- D − ) Total

Test Positive ( T + T+ T + ) a a a (True Positive) b b b (False Positive) a + b a+b a + b (Total Test Positives)

Test Negative ( T − T- T − ) c c c (False Negative) d d d (True Negative) c + d c+d c + d (Total Test Negatives)

Total a + c a+c a + c (Total Diseased) b + d b+d b + d (Total Non-Diseased) N = a + b + c + d N = a+b+c+d N = a + b + c + d

  • 3. Core Validity Metrics: Sensitivity & Specificity
  • A. Sensitivity (True Positive Rate)

The probability that a diseased individual tests positive. Sensitivity = a a + c × 100 \text{Sensitivity} = \frac{a}{a+c} \times 100 Sensitivity = a + c a ​ × 100

Clinical Rule (SNOUT) : A S ensitive test, when N egative, rules OUT the disease. (High sensitivity means very few false negatives c c c ).

Indication : Mandatory when screening for serious, highly transmissible, or treatable conditions (e.g., Blood donor screening for HIV/Hepatitis B; Pap smear screening).

B. Specificity (True Negative Rate)

The probability that a non-diseased individual tests negative. Specificity = d b + d × 100 \text{Specificity} = \frac{d}{b+d} \times 100 Specificity = b + d d ​ × 100

Clinical Rule (SPIN) : A S pecific test, when P ositive, rules IN the disease. (High specificity means very few false positives b b b ).

Indication : Mandatory when false-positive results cause severe physical, psychological, or financial harm (e.g., Confirmatory Western Blot; initiating cancer chemotherapy).

C. Error Rates

False Positive Rate (FPR) = 1 − Specificity = b b + d 1 - \text{Specificity} = \frac{b}{b+d} 1 − Specificity = b + d b ​

False Negative Rate (FNR) = 1 − Sensitivity = c a + c 1 - \text{Sensitivity} = \frac{c}{a+c} 1 − Sensitivity = a + c c ​

  • 4. Predictive Values & Influence of Disease Prevalence
  • A. Positive Predictive Value (PPV)

The probability that a person who tests positive actually has the disease. PPV = a a + b × 100 \text{PPV} = \frac{a}{a+b} \times 100 PPV = a + b a ​ × 100

B. Negative Predictive Value (NPV)

The probability that a person who tests negative is truly free of the disease. NPV = d c + d × 100 \text{NPV} = \frac{d}{c+d} \times 100 NPV = c + d d ​ × 100

C. Impact of Disease Prevalence on Predictive Values

UPSC CMS High-Yield Concept : Sensitivity and Specificity are intrinsic properties of a screening test and DO NOT change with disease prevalence. However, PPV and NPV are heavily dependent on disease prevalence :

As Prevalence Rises : PPV increases dramatically ; NPV decreases slightly.

As Prevalence Falls : PPV drops sharply (resulting in high proportions of false positives among test-positives); NPV increases toward 100%. +---------------------------------------------------------------------------------------------------+

  • | EFFECT OF PREVALENCE ON PREDICTIVE VALUE (Fixed Sens = 90%, Spec = 90%) |
  • +-----------------------+-----------------------+-----------------------+---------------------------+
  • | Disease Prevalence | True Positives (a) | False Positives (b) | Positive Predictive Value |
  • +-----------------------+-----------------------+-----------------------+---------------------------+
  • | High Prevalence (20%) | 180 per 1,000 | 80 per 1,000 | PPV = 180/260 = 69.2% |
  • | Low Prevalence (1%) | 9 per 1,000 | 99 per 1,000 | PPV = 9/108 = 8.3% |
  • +-----------------------+-----------------------+-----------------------+---------------------------+
  • 5. Multiple Testing Strategies: Parallel vs. Serial
  • A. Parallel Testing (Simultaneous)

Two or more screening tests are administered concurrently. A positive result on ANY single test classifies the individual as test-positive.

Effect : Maximizes overall Sensitivity and NPV ; reduces overall Specificity.

Clinical Application : Emergency room evaluation (e.g., combining ECG + Troponin T for acute myocardial infarction).

B. Serial / Sequential Testing

Tests are performed in sequence; the second test is administered ONLY if the first test is positive . An individual is classified as positive only if ALL tests are positive .

Effect : Maximizes overall Specificity and PPV ; reduces overall Sensitivity.

Clinical Application : Two-tier screening (e.g., initial ELISA screening followed by confirmatory Western Blot or PCR).

  • 6. Advanced Screening Metrics & Evaluation Biases
  • Receiver Operating Characteristic (ROC) Curve

An ROC curve plots Sensitivity (y-axis) against 1 - Specificity (x-axis) across continuous diagnostic cut-off thresholds.

The Area Under the Curve (AUC) evaluates overall diagnostic accuracy (AUC = 1.0 represents a perfect test; AUC = 0.5 represents a useless test equivalent to chance).

Screening Evaluation Biases

Lead Time Bias : The apparent inflation in survival time caused by detecting disease earlier in its natural history (at screening) without actually altering the ultimate age at death.

Length Time Bias : The over-representation of slowly progressing, indolent cases (having longer preclinical phases) among screen-detected cases compared to rapidly fatal cases.

Loading diagram... 2x2 Screening Matrix & Performance Metrics Derived Flowchart